- Home
- CHGG vs IFRX Comparison
CHGG vs IFRX Comparison
Compare CHGG & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHGG
- IFRX
- Stock Information
- Founded
- CHGG 2005
- IFRX 2007
- Country
- CHGG United States
- IFRX Germany
- Employees
- CHGG N/A
- IFRX N/A
- Industry
- CHGG Other Consumer Services
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- CHGG Real Estate
- IFRX Health Care
- Exchange
- CHGG Nasdaq
- IFRX Nasdaq
- Market Cap
- CHGG 90.2M
- IFRX 117.8M
- IPO Year
- CHGG 2013
- IFRX 2017
- Fundamental
- Price
- CHGG $0.78
- IFRX $1.15
- Analyst Decision
- CHGG Sell
- IFRX Strong Buy
- Analyst Count
- CHGG 7
- IFRX 1
- Target Price
- CHGG $2.08
- IFRX $8.00
- AVG Volume (30 Days)
- CHGG 4.6M
- IFRX 623.9K
- Earning Date
- CHGG 04-28-2025
- IFRX 05-07-2025
- Dividend Yield
- CHGG N/A
- IFRX N/A
- EPS Growth
- CHGG N/A
- IFRX N/A
- EPS
- CHGG N/A
- IFRX N/A
- Revenue
- CHGG $617,574,000.00
- IFRX $187,930.00
- Revenue This Year
- CHGG N/A
- IFRX $396.02
- Revenue Next Year
- CHGG N/A
- IFRX $155.22
- P/E Ratio
- CHGG N/A
- IFRX N/A
- Revenue Growth
- CHGG N/A
- IFRX 177.12
- 52 Week Low
- CHGG $0.75
- IFRX $1.14
- 52 Week High
- CHGG $8.15
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- CHGG 31.20
- IFRX 24.46
- Support Level
- CHGG $0.75
- IFRX $1.76
- Resistance Level
- CHGG $0.88
- IFRX $1.34
- Average True Range (ATR)
- CHGG 0.13
- IFRX 0.14
- MACD
- CHGG -0.02
- IFRX -0.01
- Stochastic Oscillator
- CHGG 3.24
- IFRX 1.39
About CHGG Chegg Inc.
Chegg Inc is an American educational services company. The Chegg platform provides products and services to support learners with their academic course materials, as well as their career and personal skills development. The company's service and product offerings fall into two categories: Subscription Services, which encompasses Chegg Study Pack, Chegg Study, Chegg Writing, Chegg Math, and Busuu offerings that can be accessed internationally through the company's websites and on mobile devices, and Skills and Other, which encompasses skills, advertising services, print textbooks, and eTextbooks offerings.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.